Linesight’s client is building a new facility dedicated to the development and manufacturing of viral vectors. The new facility will be constructed within an existing biologics operations facility and will help build on our confidential client’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer.
The new facility will be approximately 67,000 sq. ft. and consist of two multi-product viral vector manufacturing suites, two cell expansion suites, two filling suites, as well as warehousing, shipping and receiving, final product storage, working cell bank storage, quality control laboratories, and office and support areas for employees.
Data
Size
status
Relevant Projects
Latest Insights
29th April 2024
Exploring emerging trends in sustainable construction cost management practices
Conrad Gorny, Associate Director, and Danielle Hurley, ESG Program Lead, shed light on some of key trends shaping sustainable construction cost management practices.
Continue Reading21 March 2024
Construction Market Insights - Europe
21 March 2024
Construction Market Insights - Americas